These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15983899)

  • 1. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
    Ehlers S
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S199-203. PubMed ID: 15983900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.
    Wallis RS; Ehlers S
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):34-8. PubMed ID: 15852254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
    Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
    Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Wallis RS
    Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.
    Kast RE; Altschuler EL
    J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY; Sofer C; Stein DS; Schwander SK; Wallis RS
    J Infect Dis; 2006 Aug; 194(4):486-92. PubMed ID: 16845632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.
    Grattendick KJ; Nakashima JM; Feng L; Giri SN; Margolin SB
    Int Immunopharmacol; 2008 May; 8(5):679-87. PubMed ID: 18387510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
    Furst DE; Wallis R; Broder M; Beenhouwer DO
    Semin Arthritis Rheum; 2006 Dec; 36(3):159-67. PubMed ID: 16884970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.